8RAS (KRAS/NRAS) gene mutations are detected in approximately 50% of patients with unresectable colorectal cancer, and it was reported that the efficacy of anti-EGFR antibody therapy (CET, PANI) cannot be expected for patients with these mutations. Here, EGFR is linked to colorectal cancer.